Journal article

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.

Viviana Galimberti, Bernard F Cole, Giuseppe Viale, Paolo Veronesi, Elisa Vicini, Mattia Intra, Giovanni Mazzarol, Samuele Massarut, Janez Zgajnar, Mario Taffurelli, David Littlejohn, Michael Knauer, Carlo Tondini, Angelo Di Leo, Marco Colleoni, Meredith M Regan, Alan S Coates, Richard D Gelber, Aron Goldhirsch, undefined International Breast Cancer Study Group Trial 23-01

Lancet Oncol | Elsevier BV | Published : 2018


BACKGROUND: We previously reported the 5-year results of the phase 3 IBCSG 23-01 trial comparing disease-free survival in patients with breast cancer with one or more micrometastatic (≤2 mm) sentinel nodes randomly assigned to either axillary dissection or no axillary dissection. The results showed no difference in disease-free survival between the groups and showed non-inferiority of no axillary dissection relative to axillary dissection. The current analysis presents the results of the study after a median follow-up of 9·7 years (IQR 7·8-12·7). METHODS: In this multicentre, randomised, controlled, open-label, non-inferiority, phase 3 trial, participants were recruited from 27 hospitals and..

View full abstract